HRP20100364T1 - Stabilizirana formulacija cefalosporinskih derivata, osušena smrzavanjem - Google Patents
Stabilizirana formulacija cefalosporinskih derivata, osušena smrzavanjem Download PDFInfo
- Publication number
- HRP20100364T1 HRP20100364T1 HR20100364T HRP20100364T HRP20100364T1 HR P20100364 T1 HRP20100364 T1 HR P20100364T1 HR 20100364 T HR20100364 T HR 20100364T HR P20100364 T HRP20100364 T HR P20100364T HR P20100364 T1 HRP20100364 T1 HR P20100364T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydrogen
- ocor
- freeze
- cephalosporin
- mannitol
- Prior art date
Links
- 229930186147 Cephalosporin Natural products 0.000 title claims abstract 17
- 229940124587 cephalosporin Drugs 0.000 title claims abstract 17
- 150000001780 cephalosporins Chemical class 0.000 title claims abstract 16
- 238000009472 formulation Methods 0.000 title claims abstract 14
- 239000000203 mixture Substances 0.000 title claims abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 16
- 239000001257 hydrogen Substances 0.000 claims abstract 16
- 150000001875 compounds Chemical class 0.000 claims abstract 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract 8
- 229930195725 Mannitol Natural products 0.000 claims abstract 8
- 239000000594 mannitol Substances 0.000 claims abstract 8
- 235000010355 mannitol Nutrition 0.000 claims abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 7
- 150000002431 hydrogen Chemical class 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 4
- 239000003381 stabilizer Substances 0.000 claims abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 239000011737 fluorine Substances 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims 5
- 239000007864 aqueous solution Substances 0.000 claims 4
- 239000007853 buffer solution Substances 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 125000001271 cephalosporin group Chemical group 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000010979 pH adjustment Methods 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Formulacija cefalosporinskih derivata, osušena smrzavanjem, naznačena time što je farmaceutski prihvatljiva, sadrži najmanje jedan cefalosporinski derivat kao aktivni sastojak, gdje navedeni cefalosporinski derivat je spoj sljedeće opće formule IgdjeR1 je vodik, C1-6-alkil, izborno supstituiran s fluorom, ili C3-6-cikloalkil; R2 je vodik ili skupina koju se bira između -CH2C(=CHR)-COOR, -CH2OCOR, -CH(R)OCOR, -CH(R)OCOOR, -CH(OCOR)OCOR, -CH2COCH2OCOR iR3 je vodik ili skupina koju se bira između -CH2C(=CH2)-COOR, -COOCH2C(=CHR)-COOR, -COOCH2OCOR, -COOCH(R)OCOR, -COOCH(R)OCOOR, -COOCH(OCOR)OCOR, -COOCH2COCH2OCOR, teuz uvjet da jedan od R2 i R3 je vodik, a drugi od R2 i R3 nije vodik, R je vodik ili C1-6-alkil; R4 je vodik ili hidroksi, R5 je vodik ili ω-hidroksialkil; iX je CH ili N, kao i farmaceutski prihvatljive soli i polimorfi navedenih spojeva i hidrata spojeva formule I i njihovih solii manitol kao stabilizator. Patent sadrži još 11 patentnih zahtjeva.
Claims (12)
1. Formulacija cefalosporinskih derivata, osušena smrzavanjem, naznačena time što je farmaceutski prihvatljiva, sadrži najmanje jedan cefalosporinski derivat kao aktivni sastojak, gdje navedeni cefalosporinski derivat je spoj sljedeće opće formule I
[image]
gdje
R1 je vodik, C1-6-alkil, izborno supstituiran s fluorom, ili C3-6-cikloalkil;
R2 je vodik ili skupina koju se bira između -CH2C(=CHR)-COOR, -CH2OCOR, -CH(R)OCOR, -CH(R)OCOOR, -CH(OCOR)OCOR, -CH2COCH2OCOR i
[image]
R3 je vodik ili skupina koju se bira između -CH2C(=CH2)-COOR, -COOCH2C(=CHR)-COOR, -COOCH2OCOR, -COOCH(R)OCOR, -COOCH(R)OCOOR, -COOCH(OCOR)OCOR, -COOCH2COCH2OCOR, te
[image]
uz uvjet da jedan od R2 i R3 je vodik, a drugi od R2 i R3 nije vodik,
R je vodik ili C1-6-alkil;
R4 je vodik ili hidroksi,
R5 je vodik ili ω-hidroksialkil; i
X je CH ili N,
kao i farmaceutski prihvatljive soli i polimorfi navedenih spojeva i hidrata spojeva formule I i njihovih soli
i manitol kao stabilizator.
2. Formulacija osušena smrzavanjem, u skladu s patentnim zahtjevom 1, naznačena time što cefalosporinski derivat je (6R,7R)-7-[(Z)-2-(amino-1,2,4-tiadiazol-3-il)-2-hidroksiiminoacetilamino]-3-[(E)-(3'R,5'R)-5'-hidroksimetil-1'-(5-metil-2-okso-1,3-dioksol-4-ilmetiloksikarbonil-2-okso-1,3'-bipirolidinil-3-ilidenemetil)-8-okso-5-tia-1-azabiciklo[4.2.0]okt-2-en-2-karboksilna kiselina.
3. Formulacija osušena smrzavanjem, u skladu s patentnim zahtjevom 1 ili 2, naznačena time što dodatno sadrži jedan ili više spojeva, koje se bira između pufera, aminokiselina, kiselina ili baza za podešavanje pH, surfaktanata, soli, konzervansa, antioksidansa i kelirajućih sredstava.
4. Formulacija osušena smrzavanjem, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je namijenjena rekonstituciji otopine, radi parenteralne intramuskularne primjene, oralne primjene ili inhalacijom; ili radi izravne oralne primjene ili inhalacije.
5. Formulacija u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačena time što je dobivena sušenjem smrzavanjem otopine koja sadrži najmanje jedan cefalosporin kao aktivni sastojak, gdje cefalosporin je spoj formule I, kao što je definirana u patentnom zahtjevu 1, manitol i vodenu otopinu.
6. Formulacija u skladu s patentnim zahtjevom 5, naznačena time što vodena otopina je puferska otopina.
7. Formulacija u skladu s patentnim zahtjevom 6, naznačena time što puferska otopina je vodeni citratni pufer.
8. Formulacija u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačena time što koncentracija manitola je u rasponu od 2-40 %, težinski.
9. Formulacija u skladu s bilo kojim od patentnih zahtjeva 5 do 8, naznačena time što pH otopine je u rasponu od 2,0-6,5, a osobito u rasponu od 4,0-5,0.
10. Otopina namijenjena dobivanju formulacije osušene smrzavanjem, naznačena time što sadrži najmanje jedan cefalosporinski derivat kao aktivni sastojak, gdje cefalosporinski derivat je spoj formule I, kao što je definirana u patentnom zahtjevu 1, i stabilizator, koji je manitol, u vodenoj otopini.
11. Postupak priprave stabilizirane farmaceutski prihvatljive formulacije cefalosporinskih derivata, osušene smrzavanjem, gdje cefalosporinski derivat je spoj formule I, kao što je definirana u patentnom zahtjevu 1, naznačen time što se sastoji u koracima
(a) dodavanja manitola kao stabilizatora u vodenu otopinu cefalosporinskog derivata; i
(b) sušenja smrzavanjem gore navedene otopine.
12. Upotreba manitola, naznačena time što manitol je namijenjen stabiliziranju cefalosporinskih derivata, gdje cefalosporinski derivat je spoj formule I, kao što je definirana u patentnom zahtjevu 1, u formulacijama osušenim smrzavanjem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04405690A EP1656930A1 (en) | 2004-11-10 | 2004-11-10 | Stabilized freeze-dried formulation for cephalosporin derivatives |
| PCT/CH2005/000665 WO2006050631A1 (en) | 2004-11-10 | 2005-11-10 | Stabilized freeze-dried formulation for cephalosporin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100364T1 true HRP20100364T1 (hr) | 2010-07-31 |
Family
ID=34932353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100364T HRP20100364T1 (hr) | 2004-11-10 | 2010-06-29 | Stabilizirana formulacija cefalosporinskih derivata, osušena smrzavanjem |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20080032962A1 (hr) |
| EP (3) | EP1656930A1 (hr) |
| JP (1) | JP2008519775A (hr) |
| KR (1) | KR20070084150A (hr) |
| CN (1) | CN101056623B (hr) |
| AR (1) | AR052233A1 (hr) |
| AT (1) | ATE468844T1 (hr) |
| AU (1) | AU2005304252B2 (hr) |
| BR (1) | BRPI0517305A (hr) |
| CA (1) | CA2585296A1 (hr) |
| CY (1) | CY1110731T1 (hr) |
| DE (1) | DE602005021530D1 (hr) |
| DK (1) | DK1809253T3 (hr) |
| ES (1) | ES2342833T3 (hr) |
| HR (1) | HRP20100364T1 (hr) |
| MX (1) | MX2007005677A (hr) |
| MY (1) | MY142648A (hr) |
| PL (1) | PL1809253T3 (hr) |
| PT (1) | PT1809253E (hr) |
| RS (1) | RS51380B (hr) |
| SI (1) | SI1809253T1 (hr) |
| TW (1) | TW200630118A (hr) |
| WO (1) | WO2006050631A1 (hr) |
| ZA (1) | ZA200703760B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080103121A1 (en) * | 2006-10-30 | 2008-05-01 | Gole Dilip J | Cephalosporin derivative formulation |
| CA2672154C (en) * | 2006-12-07 | 2014-11-18 | Daiichi Sankyo Company, Limited | Pharmaceutical composition having improved storage stability |
| BRPI0719393B8 (pt) | 2006-12-07 | 2021-05-25 | Daiichi Sankyo Co Ltd | composição farmacêutica |
| EP2257159A4 (en) * | 2008-03-04 | 2011-05-11 | Elan Pharma Int Ltd | STABLE LIQUID FORMULATIONS OF ANTI-INFECTIOUS AGENTS AND ADJUSTED DOSAGE REGIMES OF ANTI-INFECTIOUS AGENTS |
| EP2106788A1 (en) * | 2008-04-04 | 2009-10-07 | Ipsen Pharma | Liquid and freeze dried formulations |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US20130089638A1 (en) | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
| CN102716075B (zh) * | 2012-07-03 | 2013-08-21 | 哈药集团制药总厂 | 一种含有头孢唑肟钠的药物组合物 |
| CN102727451B (zh) * | 2012-07-03 | 2013-07-03 | 哈药集团制药总厂 | 一种含有头孢美唑钠的药物组合物 |
| CN103271877A (zh) * | 2012-12-18 | 2013-09-04 | 张宏民 | 一种头孢西丁钠注射剂及其制备方法 |
| MX361984B (es) | 2013-03-13 | 2018-12-19 | Theravance Biopharma Antibiotics Ip Llc | Sales clorhidrato de un compuesto antibiótico. |
| CN110507619B (zh) * | 2019-08-19 | 2021-12-03 | 湖北美林药业有限公司 | 注射用头孢哌酮钠及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2690009B2 (ja) * | 1986-07-10 | 1997-12-10 | エーザイ 株式会社 | セフアロスポリン注射剤 |
| DE3801179A1 (de) * | 1988-01-18 | 1989-07-27 | Hoechst Ag | Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten |
| DK0421297T3 (da) * | 1989-09-30 | 1994-01-17 | Eisai Co Ltd | Injicerbare præparater indeholdende cephalosporin som lægemiddel og anvendelse deraf |
| JPH0459730A (ja) * | 1990-06-26 | 1992-02-26 | Dai Ichi Seiyaku Co Ltd | セフェム系抗生物質含有凍結乾燥製剤 |
| BRPI9911178C1 (pt) * | 1998-06-15 | 2021-05-25 | Basilea Pharmaceutica Ag | derivados de 3-(2-oxo-[1,3']bipirrolidinil-3-ilidenometil)-cefems, bem como preparação farmacêutica e uso dos mesmos |
| US7378408B2 (en) * | 2001-11-30 | 2008-05-27 | Pfizer Inc. | Methods of treatment and formulations of cephalosporin |
| WO2004000323A1 (ja) * | 2002-06-21 | 2003-12-31 | Shionogi & Co., Ltd. | セフェム化合物の注射用医薬組成物 |
-
2004
- 2004-11-10 EP EP04405690A patent/EP1656930A1/en not_active Withdrawn
-
2005
- 2005-11-09 TW TW094139525A patent/TW200630118A/zh unknown
- 2005-11-09 AR ARP050104706A patent/AR052233A1/es not_active Application Discontinuation
- 2005-11-10 MY MYPI20055270A patent/MY142648A/en unknown
- 2005-11-10 ES ES05798682T patent/ES2342833T3/es active Active
- 2005-11-10 PT PT05798682T patent/PT1809253E/pt unknown
- 2005-11-10 CA CA002585296A patent/CA2585296A1/en not_active Abandoned
- 2005-11-10 DK DK05798682.0T patent/DK1809253T3/da active
- 2005-11-10 RS RSP-2010/0324A patent/RS51380B/en unknown
- 2005-11-10 JP JP2007540473A patent/JP2008519775A/ja active Pending
- 2005-11-10 DE DE602005021530T patent/DE602005021530D1/de active Active
- 2005-11-10 US US11/667,535 patent/US20080032962A1/en not_active Abandoned
- 2005-11-10 BR BRPI0517305-1A patent/BRPI0517305A/pt not_active IP Right Cessation
- 2005-11-10 MX MX2007005677A patent/MX2007005677A/es active IP Right Grant
- 2005-11-10 WO PCT/CH2005/000665 patent/WO2006050631A1/en active Application Filing
- 2005-11-10 KR KR1020077010624A patent/KR20070084150A/ko not_active Application Discontinuation
- 2005-11-10 PL PL05798682T patent/PL1809253T3/pl unknown
- 2005-11-10 SI SI200531069T patent/SI1809253T1/sl unknown
- 2005-11-10 EP EP10162297A patent/EP2210592A3/en not_active Withdrawn
- 2005-11-10 CN CN2005800384621A patent/CN101056623B/zh not_active Expired - Fee Related
- 2005-11-10 EP EP05798682A patent/EP1809253B1/en active Active
- 2005-11-10 AT AT05798682T patent/ATE468844T1/de active
- 2005-11-10 AU AU2005304252A patent/AU2005304252B2/en not_active Ceased
-
2007
- 2007-05-09 ZA ZA200703760A patent/ZA200703760B/en unknown
-
2010
- 2010-02-03 US US12/699,329 patent/US20100160278A1/en not_active Abandoned
- 2010-06-29 HR HR20100364T patent/HRP20100364T1/hr unknown
- 2010-08-04 CY CY20101100728T patent/CY1110731T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070084150A (ko) | 2007-08-24 |
| EP1656930A1 (en) | 2006-05-17 |
| US20100160278A1 (en) | 2010-06-24 |
| CN101056623B (zh) | 2011-04-06 |
| RS51380B (en) | 2011-02-28 |
| DK1809253T3 (da) | 2010-07-12 |
| WO2006050631A1 (en) | 2006-05-18 |
| CN101056623A (zh) | 2007-10-17 |
| MX2007005677A (es) | 2007-07-20 |
| SI1809253T1 (sl) | 2010-09-30 |
| EP2210592A3 (en) | 2011-12-14 |
| PT1809253E (pt) | 2010-09-03 |
| TW200630118A (en) | 2006-09-01 |
| CY1110731T1 (el) | 2015-06-10 |
| PL1809253T3 (pl) | 2010-10-29 |
| JP2008519775A (ja) | 2008-06-12 |
| DE602005021530D1 (de) | 2010-07-08 |
| AR052233A1 (es) | 2007-03-07 |
| EP1809253B1 (en) | 2010-05-26 |
| MY142648A (en) | 2010-12-15 |
| US20080032962A1 (en) | 2008-02-07 |
| ATE468844T1 (de) | 2010-06-15 |
| EP1809253A1 (en) | 2007-07-25 |
| AU2005304252B2 (en) | 2009-07-16 |
| ES2342833T3 (es) | 2010-07-15 |
| BRPI0517305A (pt) | 2008-10-07 |
| EP2210592A2 (en) | 2010-07-28 |
| ZA200703760B (en) | 2008-06-25 |
| CA2585296A1 (en) | 2006-05-18 |
| AU2005304252A1 (en) | 2006-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100364T1 (hr) | Stabilizirana formulacija cefalosporinskih derivata, osušena smrzavanjem | |
| JP2008509952A5 (hr) | ||
| ES2356792T3 (es) | Procedimientos para la preparación de sales farmacéuticamente aceptables liofilizadas de pemetrexed diácido. | |
| ZA200302085B (en) | 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents. | |
| DE3378827D1 (en) | Cephalosporin derivatives and process for their preparation | |
| CA2227994C (en) | Carbapenem antibiotic, composition and method of preparation | |
| RU2008121716A (ru) | Препараты | |
| KR940018380A (ko) | 퀴놀론-및 나프티리돈카르복실산 유도체 | |
| RU2015115711A (ru) | Антибиотические композиции тазобактама аргинина | |
| HU183089B (en) | Process for preparing cef-3-em-4-carboxylic acid derivatives | |
| KR890013028A (ko) | 세팔로스포린 유도체 및 이의 제법 | |
| HU211940A9 (en) | Water-soluble antibiotic composition and water-soluble salts of cephem compounds | |
| KR950008515A (ko) | 피리도[1,2,3-d,e][1,3,4] 벤족사디아진 유도체 | |
| ES2170758T3 (es) | Antibioticos novedosos de cefalosporina y procedimientos para la preparacion de los mismos. | |
| CA2662219A1 (en) | Lyophilized preparation of 1-methylcarbapenem compound | |
| KR100227009B1 (ko) | 신규 세펨 유도체 | |
| US20030162762A1 (en) | Novel cephalosporin compounds and process for preparing the same | |
| KR950008519A (ko) | 신규 세팔로스포린계 항생제 및 이의 제조방법 | |
| HU182498B (en) | Process for producing 7-bracket-iminoacetamido-bracket closed-3-thiomethyl-ceph-3-eme-4-caraoxylic acid | |
| RU2000126469A (ru) | Цефалоспорины, содержащие циклические аминогуанидиновые заместители, как антибиотики | |
| US6242437B1 (en) | Cephem derivatives | |
| KR101574875B1 (ko) | 안정화된 페니실린 복합 현탁 제제 | |
| AU640524B2 (en) | Use of folic acid for reducing the toxicity of antitumour antifolate agents and methods for treating tumours | |
| KR880007543A (ko) | 세팔로스포린유도체를 유효성분으로 하는 포유동물용 항균제 | |
| CS203008B2 (en) | Process for preparing acylderivatives |